相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Ocean Biomedical's breakthrough research demonstrates their immunotherapy candidates can synergize with tyrosine kinase inhibitors like osimertinib to suppress tumor growth in EGFR-mutant lung cancer. - The study reveals the first-ever role of chitinase 3-like-1 (CHi3L1) in EGFR-mutant cancers, showing potential to restore treatment sensitivity in patients who have developed resistance to standard therapies. - The company plans to initiate FDA discussions this year for clinical development pathway, while also advancing their bispecific antibody platform targeting PD-1/CTLA4 pathways in multiple cancer types.
- Ocean Biomedical's research team, led by Dr. Jonathan Kurtis, has received $3.5 million in NIH funding to advance their innovative malaria vaccine research targeting the GARP protein. - The company is developing three vaccine candidates currently in non-human primate trials, supported by a $4.6 million foundation grant, with potential human trials starting in Q4 2025. - New FDA guidance on lipid-encapsulated vaccines may accelerate the development pathway for Ocean Biomedical's malaria vaccine, which targets a disease that claims over 500,000 children's lives annually in sub-Saharan Africa.
